GLOBAL GENETIC TESTING MARKET FORECAST 2018-2026
KEY FINDINGS
Rise in the prevalence of genetic disorders is a key driver for the global genetic testing market. The market, which stood at $ 5054 million in 2017, is expected to rise at 9.97% CAGR over the forecast period of 2018- 2026 and is predicted to generate $11856 million by its end.
MARKT INSIGHTS
Market segmentation is done on the basis of applications and testing types. Global genetic testing market by applications include areas like prenatal, cancer, pharmacogenomics and predispositions. Genetic testing market by type is segmented into diagnostic testing, predictive and presymptomatic testing, preimplantation genetic diagnosis and newborn and prenatal testing.
REGIONAL INSIGHTS
Regional segmentation of the market is done into Asia, Europe, North America and rest of world. The Asia-Pacific market is predicted to grow with the fastest CAGR while the North American market is expected to capture the largest revenue share by the end of the forecast period. The APC market is driven by growing research in molecular biology applications, infectious disease testing and cancer risk studies, while the North American market is driven by the presence of key market players.
COMPETITIVE INSIGHTS
Cepheid, Genentech Inc, Daan Diagnostics Ltd, Genomictree Inc, Illumina, Inc, HTG Molecular Diagnostics, Inc, Integragen S.A, Luminex Corporation, Laboratory Corporation Of America Holdings, Molecularmd Corp, Oxford Biodynamics Limited, Natera Inc, Pacific Biosciences Of California Inc, Qiagen N.V, Perkinelmer Inc, and Roche Diagnostics Corporation are some of the important players in this market
Rise in the prevalence of genetic disorders is a key driver for the global genetic testing market. The market, which stood at $ 5054 million in 2017, is expected to rise at 9.97% CAGR over the forecast period of 2018- 2026 and is predicted to generate $11856 million by its end.
MARKT INSIGHTS
Market segmentation is done on the basis of applications and testing types. Global genetic testing market by applications include areas like prenatal, cancer, pharmacogenomics and predispositions. Genetic testing market by type is segmented into diagnostic testing, predictive and presymptomatic testing, preimplantation genetic diagnosis and newborn and prenatal testing.
REGIONAL INSIGHTS
Regional segmentation of the market is done into Asia, Europe, North America and rest of world. The Asia-Pacific market is predicted to grow with the fastest CAGR while the North American market is expected to capture the largest revenue share by the end of the forecast period. The APC market is driven by growing research in molecular biology applications, infectious disease testing and cancer risk studies, while the North American market is driven by the presence of key market players.
COMPETITIVE INSIGHTS
Cepheid, Genentech Inc, Daan Diagnostics Ltd, Genomictree Inc, Illumina, Inc, HTG Molecular Diagnostics, Inc, Integragen S.A, Luminex Corporation, Laboratory Corporation Of America Holdings, Molecularmd Corp, Oxford Biodynamics Limited, Natera Inc, Pacific Biosciences Of California Inc, Qiagen N.V, Perkinelmer Inc, and Roche Diagnostics Corporation are some of the important players in this market
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
2.5. ESTIMATION METHODOLOGY
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. ASIA PACIFIC IS THE FASTEST GROWING REGION
3.2.2. DIAGNOSTIC TESTING IS LEADING THE GENETIC TESTING MARKET BY TYPE
3.2.3. CANCER MARKET HOLDS THE LARGEST MARKET SHARE, BY APPLICATIONS
4. MARKET DETERMINANTS
4.1. MARKET DRIVERS
4.1.1. DIAGNOSING GENETIC DISORDERS
4.1.2. RISE IN INCIDENCE OF GENETIC DISEASES
4.1.3. SIMPLE ACCESSIBLE PROCEDURE
4.1.4. RNA PIPELINE TESTS RISING
4.1.5. ADVANCES IN GENETIC TESTING FOR CANCER
4.1.6. AGING POPULATION ON THE RISE
4.2. MARKET RESTRAINTS
4.2.1. INACCURACIES IN RESULTS
4.2.2. REIMBURSEMENT ISSUES
4.2.3. PSYCHOLOGICAL IMPACT
4.2.4. LACK OF PRECISION IN TESTING
4.3. MARKET OPPORTUNITIES
4.3.1. GENETIC COUNSELLING
4.3.2. EXPANSION OF BREAST CANCER GENES TESTING MARKET
4.3.3. NEW AND IMPROVED TECHNOLOGY
4.4. MARKET CHALLENGES
4.4.1. HIGH COST OF MEDICATION AND TESTS
4.4.2. HIGH COST OF RAW MATERIAL
4.4.3. RISE IN GENETIC DISCRIMINATION
5. MARKET SEGMENTATION
5.1. MARKET BY TYPES 2018-2026
5.1.1. PREDICTIVE AND PRESYMPTOMATIC TESTING
5.1.2. DIAGNOSTIC TESTING
5.1.3. NEWBORN AND PRENATAL TESTING
5.1.3.1. SCREENING METHODS
5.1.3.1.1. NIPT
5.1.3.1.2. MSS
5.1.3.2. DIAGNOSTIC TECHNIQUES
5.1.3.2.1. PCR
5.1.3.2.2. FISH
5.1.3.2.3. CGH
5.1.4. PREIMPLANTATION GENETIC DIAGNOSIS
5.2. MARKET BY APPLICATION 2018-2026
5.2.1. CANCER GENETIC TESTING
5.2.2. PRENATAL GENETIC TESTING
5.2.3. PHARMACOGENOMICS
5.2.4. PREDISPOSITION MARKET
6. KEY ANALYTICS
6.1. PORTER’S FIVE FORCES ANALYSIS
6.1.1. THREAT OF NEW ENTRANTS
6.1.2. THREAT OF SUBSTITUTES
6.1.3. BARGAINING POWER OF BUYERS
6.1.4. BARGAINING POWER OF SUPPLIERS
6.1.5. THREAT OF RIVALRY
6.2. KEY BUYING CRITERIA
6.2.1. COST
6.2.2. ACCURACY
6.2.3. AVAILABILITY
6.2.4. RELIABILITY
6.3. MARKET TRENDS
6.3.1. HEALTH INFORMATION IS RISING SIGNIFICANTLY
6.3.2. INCREASING DEMAND FOR PERSONALIZED MEDICINE
6.3.3. NEW PRODUCT LAUNCHES
6.3.4. TECHNOLOGY ADVANCEMENTS
7. GEOGRAPHIC ANALYSIS
7.1. NORTH AMERICA
7.1.1. UNITED STATES (U.S.)
7.1.2. CANADA
7.2. EUROPE
7.2.1. UNITED KINGDOM
7.2.2. FRANCE
7.2.3. GERMANY
7.2.4. SPAIN
7.2.5. ITALY
7.2.6. REST OF EUROPE
7.3. ASIA PACIFIC
7.3.1. INDIA
7.3.2. CHINA
7.3.3. JAPAN
7.3.4. KOREA
7.3.5. REST OF APAC
7.4. REST OF THE WORLD
7.4.1. LATIN AMERICA
7.4.2. MIDDLE EAST AND NORTH AFRICA
7.4.3. REST OF AFRICA
8. COMPANY PROFILING
8.1. CEPHEID
8.2. DAAN DIAGNOSTICS LTD.
8.3. GENENTECH, INC
8.4. GENOMICTREE, INC.
8.5. HTG MOLECULAR DIAGNOSTICS, INC.
8.6. ILLUMINA, INC
8.7. INTEGRAGEN S.A
8.8. LABORATORY CORPORATION OF AMERICA HOLDINGS
8.9. LUMINEX CORPORATION
8.10. MOLECULARMD, CORP
8.11. NATERA, INC
8.12. OXFORD BIODYNAMICS LIMITED
8.13. PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
8.14. PERKINELMER, INC.
8.15. QIAGEN N.V.
8.16. ROCHE DIAGNOSTICS CORPORATION
TABLE LIST
TABLE 1 GLOBAL GENETIC TESTING MARKET BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 2 COST OF SELECTED DRUGS IN CANCER THERAPY
TABLE 3 GLOBAL GENETIC TESTING MARKET BY TYPE 2018-2026 ($ MILLION)
TABLE 4 GLOBAL GENETIC TESTING MARKET IN PREDICTIVE AND PRESYMPTOMATIC TESTING BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 5 GLOBAL GENETIC TESTING MARKET IN DIAGNOSTIC TESTING BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 6 GLOBAL NEWBORN AND PRENATAL TESTING MARKET BY TECHNOLOGY 2018-2026 ($ MILLION)
TABLE 7 CORE DISORDERS ASSOCIATED WITH NEWBORN SCREENING
TABLE 8 GLOBAL GENETIC TESTING MARKET IN NEWBORN AND PRENATAL TESTING BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 9 COMPARISON BETWEEN SCREENINGS VERSUS DIAGNOSTIC TESTING
TABLE 10 GLOBAL NEWBORN AND PRENATAL TESTING IN SCREENING METHOD 2018-2026 ($ MILLION)
TABLE 11 GLOBAL NEWBORN AND PRENATAL TESTING IN DIAGNOSTIC TECHNIQUES 2018-2026 ($ MILLION)
TABLE 12 GLOBAL GENETIC TESTING MARKET BY APPLICATION 2018-2026 ($ MILLION)
TABLE 13 GENETICALLY LINKED CANCER
TABLE 14 NORTH AMERICA GENETIC TESTING MARKET BY COUNTRY 2018-2026 ($ MILLION)
TABLE 15 INCIDENCE RATES OF LEADING CHRONIC DISORDERS IN EUROPE, 2015
TABLE 16 EUROPE GENETIC TESTING MARKET 2018-2026
TABLE 17 PERCENTAGE OF DEATHS OF ALL AGES (ALL AGES) IN UK, 2015
TABLE 18 ASIA PACIFIC GLOBAL GENETIC TESTING MARKET BY COUNTRIES 2018-2026 ($ MILLION)
TABLE 19 REST OF WORLD GENETIC TESTING MARKET 2018-2026 ($ MILLION)
FIGURE LIST
FIGURE 1 GLOBAL GENETIC TESTING MARKET BY GEOGRAPHY 2018-2026 ($ MILLION)
FIGURE 2 SAMPLES TYPES IN GENETIC TESTING
FIGURE 3 GLOBAL GERIATRIC POPULATION (65+) 2015 & 2020 (MILLION)
FIGURE 4 PROJECTIONS FOR THE PROPORTION OF GERIATRIC (60+) POPULATION IN 2015, 2030 & 2050
FIGURE 5 LAB AUTOMATION TECHNOLOGY BENEFITS GENETIC DIAGNOSTIC INDUSTRIES
FIGURE 6 GLOBAL GENETIC TESTING MARKET BY TYPE 2018-2026 ($ MILLION)
FIGURE 7 GLOBAL GENETIC TESTING MARKET IN PREDICTIVE AND PRESYMPTOMATIC TESTING 2018-2026 ($ MILLION)
FIGURE 8 GLOBAL GENETIC TESTING MARKET IN DIAGNOSTIC TESTING 2018-2026 ($ MILLION)
FIGURE 9 GLOBAL NEWBORN AND PRENATAL TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 10 NEWBORN SCREENING IN UNITED STATES
FIGURE 11 FACTORS FOR BIRTH DEFECTS
FIGURE 12 GLOBAL SCREENING METHODS IN NIPT 2018-2026 ($ MILLION)
FIGURE 13 GLOBAL SCREENING METHODS IN MSS 2018-2026 ($ MILLION)
FIGURE 14 GLOBAL DIAGNOSTIC TECHNIQUES IN PCR 2018-2026 ($ MILLION)
FIGURE 15 GLOBAL DIAGNOSTIC TECHNIQUES IN FISH 2018-2026 ($ MILLION)
FIGURE 16 GLOBAL DIAGNOSTIC TECHNIQUES IN CGH 2018-2026 ($ MILLION)
FIGURE 17 GLOBAL GENETIC TESTING MARKET IN PREIMPLANTATION GENETIC DIAGNOSIS 2018-2026 ($ MILLION)
FIGURE 18 GLOBAL GENETIC TESTING MARKET BY APPLICATION 2018-2026
FIGURE 19 GLOBAL GENETIC TESTING MARKET FOR CANCER GENETIC TESTING 2018-2026 ($ MILLION)
FIGURE 20 GLOBAL NEW CANCER CASES AND MORTALITY RATE IN MILLION (2015-2030)
FIGURE 21 GLOBAL GENETIC TESTING MARKET IN PRENATAL 2018-2026 ($ MILLION)
FIGURE 22 GLOBAL GENETIC TESTING MARKET IN PHARMACOGENOMICS 2018-2026 ($ MILLION)
FIGURE 23 GLOBAL GENETIC TESTING MARKET IN PREDISPOSITION 2018-2026 ($ MILLION)
FIGURE 24 NUMBER OF NEW CASES FOUND IN THE NORTH AMERICAN COUNTRIES 2016
FIGURE 25 NORTH AMERICA RESPIRATORY CARE DEVICE MARKET SHARE BY COUNTRIES
FIGURE 26 CANCER CASES IN THE U.S. 2016
FIGURE 27 HEALTHCARE EXPENDITURE IN THE U.S. 2014-2025 (% OF GDP)
FIGURE 28 GLOBAL UNITED STATES GENETIC TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 29 TYPES OF NEW CASES OF CANCER IN CANADA 2015
FIGURE 30 HEALTHCARE FINANCING IN CANADA 2015 (%)
FIGURE 31 CANADA GENETIC TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 32 UNITED KINGDOM GENETIC TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 33 PERCENTAGE OF DEATHS IN FRANCE, 2015
FIGURE 34 FRANCE GENETIC TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 35 PERCENTAGE OF ALL DEATHS (ALL AGES) IN GERMANY, 2015
FIGURE 36 GERMANY GENETIC TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 37 PERCENTAGE OF DEATHS IN SPAIN, 2015
FIGURE 38 SPAIN GENETIC TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 39 ITALY GENETIC TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 40 REST OF EUROPE GENETIC TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 41 PERCENTAGE OF AGING POPULATION IN ASIA 2010 AND 2050
FIGURE 42 CANCER INCIDENCE RATE IN ASIAN COUNTRIES BY GENDER 2015
FIGURE 43 INDIA GENETIC TESTING MARKET 2018-2026($ MILLION)
FIGURE 44 CHINA GENETIC TESTING MARKET 2018-2026 ($MILLION)
FIGURE 45 JAPAN GENETIC TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 46 BIOTECHNOLOGY COMPANIES IN KOREA 2015
FIGURE 47 KOREA GENETIC TESTING MARKET 2018-2026($ MILLION)
FIGURE 48 REST OF APAC GENETIC TESTING MARKET 2018-2026($ MILLION)
FIGURE 49 REST OF WORLD GENETIC TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 50 CHRONIC DISEASE DEATH RATES (PER 100,000), 2015
FIGURE 51 TYPE OF DISEASES IN LATIN AMERICA 2015 (%)
FIGURE 52 LATIN AMERICA GENETIC TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 53 MENA GENETIC TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 54 REST OF AFRICA GENETIC TESTING MARKET 2018-2026 ($ MILLION)
COMPANIES MENTIONED
1. CEPHEID
2. DAAN DIAGNOSTICS LTD.
3. GENENTECH, INC
4. GENOMICTREE, INC.
5. HTG MOLECULAR DIAGNOSTICS, INC.
6. ILLUMINA, INC
7. INTEGRAGEN S.A
8. LABORATORY CORPORATION OF AMERICA HOLDINGS
9. LUMINEX CORPORATION
10. MOLECULARMD, CORP
11. NATERA, INC
12. OXFORD BIODYNAMICS LIMITED
13. PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
14. PERKINELMER, INC.
15. QIAGEN N.V.
16. ROCHE DIAGNOSTICS CORPORATION
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
2.5. ESTIMATION METHODOLOGY
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. ASIA PACIFIC IS THE FASTEST GROWING REGION
3.2.2. DIAGNOSTIC TESTING IS LEADING THE GENETIC TESTING MARKET BY TYPE
3.2.3. CANCER MARKET HOLDS THE LARGEST MARKET SHARE, BY APPLICATIONS
4. MARKET DETERMINANTS
4.1. MARKET DRIVERS
4.1.1. DIAGNOSING GENETIC DISORDERS
4.1.2. RISE IN INCIDENCE OF GENETIC DISEASES
4.1.3. SIMPLE ACCESSIBLE PROCEDURE
4.1.4. RNA PIPELINE TESTS RISING
4.1.5. ADVANCES IN GENETIC TESTING FOR CANCER
4.1.6. AGING POPULATION ON THE RISE
4.2. MARKET RESTRAINTS
4.2.1. INACCURACIES IN RESULTS
4.2.2. REIMBURSEMENT ISSUES
4.2.3. PSYCHOLOGICAL IMPACT
4.2.4. LACK OF PRECISION IN TESTING
4.3. MARKET OPPORTUNITIES
4.3.1. GENETIC COUNSELLING
4.3.2. EXPANSION OF BREAST CANCER GENES TESTING MARKET
4.3.3. NEW AND IMPROVED TECHNOLOGY
4.4. MARKET CHALLENGES
4.4.1. HIGH COST OF MEDICATION AND TESTS
4.4.2. HIGH COST OF RAW MATERIAL
4.4.3. RISE IN GENETIC DISCRIMINATION
5. MARKET SEGMENTATION
5.1. MARKET BY TYPES 2018-2026
5.1.1. PREDICTIVE AND PRESYMPTOMATIC TESTING
5.1.2. DIAGNOSTIC TESTING
5.1.3. NEWBORN AND PRENATAL TESTING
5.1.3.1. SCREENING METHODS
5.1.3.1.1. NIPT
5.1.3.1.2. MSS
5.1.3.2. DIAGNOSTIC TECHNIQUES
5.1.3.2.1. PCR
5.1.3.2.2. FISH
5.1.3.2.3. CGH
5.1.4. PREIMPLANTATION GENETIC DIAGNOSIS
5.2. MARKET BY APPLICATION 2018-2026
5.2.1. CANCER GENETIC TESTING
5.2.2. PRENATAL GENETIC TESTING
5.2.3. PHARMACOGENOMICS
5.2.4. PREDISPOSITION MARKET
6. KEY ANALYTICS
6.1. PORTER’S FIVE FORCES ANALYSIS
6.1.1. THREAT OF NEW ENTRANTS
6.1.2. THREAT OF SUBSTITUTES
6.1.3. BARGAINING POWER OF BUYERS
6.1.4. BARGAINING POWER OF SUPPLIERS
6.1.5. THREAT OF RIVALRY
6.2. KEY BUYING CRITERIA
6.2.1. COST
6.2.2. ACCURACY
6.2.3. AVAILABILITY
6.2.4. RELIABILITY
6.3. MARKET TRENDS
6.3.1. HEALTH INFORMATION IS RISING SIGNIFICANTLY
6.3.2. INCREASING DEMAND FOR PERSONALIZED MEDICINE
6.3.3. NEW PRODUCT LAUNCHES
6.3.4. TECHNOLOGY ADVANCEMENTS
7. GEOGRAPHIC ANALYSIS
7.1. NORTH AMERICA
7.1.1. UNITED STATES (U.S.)
7.1.2. CANADA
7.2. EUROPE
7.2.1. UNITED KINGDOM
7.2.2. FRANCE
7.2.3. GERMANY
7.2.4. SPAIN
7.2.5. ITALY
7.2.6. REST OF EUROPE
7.3. ASIA PACIFIC
7.3.1. INDIA
7.3.2. CHINA
7.3.3. JAPAN
7.3.4. KOREA
7.3.5. REST OF APAC
7.4. REST OF THE WORLD
7.4.1. LATIN AMERICA
7.4.2. MIDDLE EAST AND NORTH AFRICA
7.4.3. REST OF AFRICA
8. COMPANY PROFILING
8.1. CEPHEID
8.2. DAAN DIAGNOSTICS LTD.
8.3. GENENTECH, INC
8.4. GENOMICTREE, INC.
8.5. HTG MOLECULAR DIAGNOSTICS, INC.
8.6. ILLUMINA, INC
8.7. INTEGRAGEN S.A
8.8. LABORATORY CORPORATION OF AMERICA HOLDINGS
8.9. LUMINEX CORPORATION
8.10. MOLECULARMD, CORP
8.11. NATERA, INC
8.12. OXFORD BIODYNAMICS LIMITED
8.13. PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
8.14. PERKINELMER, INC.
8.15. QIAGEN N.V.
8.16. ROCHE DIAGNOSTICS CORPORATION
TABLE LIST
TABLE 1 GLOBAL GENETIC TESTING MARKET BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 2 COST OF SELECTED DRUGS IN CANCER THERAPY
TABLE 3 GLOBAL GENETIC TESTING MARKET BY TYPE 2018-2026 ($ MILLION)
TABLE 4 GLOBAL GENETIC TESTING MARKET IN PREDICTIVE AND PRESYMPTOMATIC TESTING BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 5 GLOBAL GENETIC TESTING MARKET IN DIAGNOSTIC TESTING BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 6 GLOBAL NEWBORN AND PRENATAL TESTING MARKET BY TECHNOLOGY 2018-2026 ($ MILLION)
TABLE 7 CORE DISORDERS ASSOCIATED WITH NEWBORN SCREENING
TABLE 8 GLOBAL GENETIC TESTING MARKET IN NEWBORN AND PRENATAL TESTING BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 9 COMPARISON BETWEEN SCREENINGS VERSUS DIAGNOSTIC TESTING
TABLE 10 GLOBAL NEWBORN AND PRENATAL TESTING IN SCREENING METHOD 2018-2026 ($ MILLION)
TABLE 11 GLOBAL NEWBORN AND PRENATAL TESTING IN DIAGNOSTIC TECHNIQUES 2018-2026 ($ MILLION)
TABLE 12 GLOBAL GENETIC TESTING MARKET BY APPLICATION 2018-2026 ($ MILLION)
TABLE 13 GENETICALLY LINKED CANCER
TABLE 14 NORTH AMERICA GENETIC TESTING MARKET BY COUNTRY 2018-2026 ($ MILLION)
TABLE 15 INCIDENCE RATES OF LEADING CHRONIC DISORDERS IN EUROPE, 2015
TABLE 16 EUROPE GENETIC TESTING MARKET 2018-2026
TABLE 17 PERCENTAGE OF DEATHS OF ALL AGES (ALL AGES) IN UK, 2015
TABLE 18 ASIA PACIFIC GLOBAL GENETIC TESTING MARKET BY COUNTRIES 2018-2026 ($ MILLION)
TABLE 19 REST OF WORLD GENETIC TESTING MARKET 2018-2026 ($ MILLION)
FIGURE LIST
FIGURE 1 GLOBAL GENETIC TESTING MARKET BY GEOGRAPHY 2018-2026 ($ MILLION)
FIGURE 2 SAMPLES TYPES IN GENETIC TESTING
FIGURE 3 GLOBAL GERIATRIC POPULATION (65+) 2015 & 2020 (MILLION)
FIGURE 4 PROJECTIONS FOR THE PROPORTION OF GERIATRIC (60+) POPULATION IN 2015, 2030 & 2050
FIGURE 5 LAB AUTOMATION TECHNOLOGY BENEFITS GENETIC DIAGNOSTIC INDUSTRIES
FIGURE 6 GLOBAL GENETIC TESTING MARKET BY TYPE 2018-2026 ($ MILLION)
FIGURE 7 GLOBAL GENETIC TESTING MARKET IN PREDICTIVE AND PRESYMPTOMATIC TESTING 2018-2026 ($ MILLION)
FIGURE 8 GLOBAL GENETIC TESTING MARKET IN DIAGNOSTIC TESTING 2018-2026 ($ MILLION)
FIGURE 9 GLOBAL NEWBORN AND PRENATAL TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 10 NEWBORN SCREENING IN UNITED STATES
FIGURE 11 FACTORS FOR BIRTH DEFECTS
FIGURE 12 GLOBAL SCREENING METHODS IN NIPT 2018-2026 ($ MILLION)
FIGURE 13 GLOBAL SCREENING METHODS IN MSS 2018-2026 ($ MILLION)
FIGURE 14 GLOBAL DIAGNOSTIC TECHNIQUES IN PCR 2018-2026 ($ MILLION)
FIGURE 15 GLOBAL DIAGNOSTIC TECHNIQUES IN FISH 2018-2026 ($ MILLION)
FIGURE 16 GLOBAL DIAGNOSTIC TECHNIQUES IN CGH 2018-2026 ($ MILLION)
FIGURE 17 GLOBAL GENETIC TESTING MARKET IN PREIMPLANTATION GENETIC DIAGNOSIS 2018-2026 ($ MILLION)
FIGURE 18 GLOBAL GENETIC TESTING MARKET BY APPLICATION 2018-2026
FIGURE 19 GLOBAL GENETIC TESTING MARKET FOR CANCER GENETIC TESTING 2018-2026 ($ MILLION)
FIGURE 20 GLOBAL NEW CANCER CASES AND MORTALITY RATE IN MILLION (2015-2030)
FIGURE 21 GLOBAL GENETIC TESTING MARKET IN PRENATAL 2018-2026 ($ MILLION)
FIGURE 22 GLOBAL GENETIC TESTING MARKET IN PHARMACOGENOMICS 2018-2026 ($ MILLION)
FIGURE 23 GLOBAL GENETIC TESTING MARKET IN PREDISPOSITION 2018-2026 ($ MILLION)
FIGURE 24 NUMBER OF NEW CASES FOUND IN THE NORTH AMERICAN COUNTRIES 2016
FIGURE 25 NORTH AMERICA RESPIRATORY CARE DEVICE MARKET SHARE BY COUNTRIES
FIGURE 26 CANCER CASES IN THE U.S. 2016
FIGURE 27 HEALTHCARE EXPENDITURE IN THE U.S. 2014-2025 (% OF GDP)
FIGURE 28 GLOBAL UNITED STATES GENETIC TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 29 TYPES OF NEW CASES OF CANCER IN CANADA 2015
FIGURE 30 HEALTHCARE FINANCING IN CANADA 2015 (%)
FIGURE 31 CANADA GENETIC TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 32 UNITED KINGDOM GENETIC TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 33 PERCENTAGE OF DEATHS IN FRANCE, 2015
FIGURE 34 FRANCE GENETIC TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 35 PERCENTAGE OF ALL DEATHS (ALL AGES) IN GERMANY, 2015
FIGURE 36 GERMANY GENETIC TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 37 PERCENTAGE OF DEATHS IN SPAIN, 2015
FIGURE 38 SPAIN GENETIC TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 39 ITALY GENETIC TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 40 REST OF EUROPE GENETIC TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 41 PERCENTAGE OF AGING POPULATION IN ASIA 2010 AND 2050
FIGURE 42 CANCER INCIDENCE RATE IN ASIAN COUNTRIES BY GENDER 2015
FIGURE 43 INDIA GENETIC TESTING MARKET 2018-2026($ MILLION)
FIGURE 44 CHINA GENETIC TESTING MARKET 2018-2026 ($MILLION)
FIGURE 45 JAPAN GENETIC TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 46 BIOTECHNOLOGY COMPANIES IN KOREA 2015
FIGURE 47 KOREA GENETIC TESTING MARKET 2018-2026($ MILLION)
FIGURE 48 REST OF APAC GENETIC TESTING MARKET 2018-2026($ MILLION)
FIGURE 49 REST OF WORLD GENETIC TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 50 CHRONIC DISEASE DEATH RATES (PER 100,000), 2015
FIGURE 51 TYPE OF DISEASES IN LATIN AMERICA 2015 (%)
FIGURE 52 LATIN AMERICA GENETIC TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 53 MENA GENETIC TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 54 REST OF AFRICA GENETIC TESTING MARKET 2018-2026 ($ MILLION)
COMPANIES MENTIONED
1. CEPHEID
2. DAAN DIAGNOSTICS LTD.
3. GENENTECH, INC
4. GENOMICTREE, INC.
5. HTG MOLECULAR DIAGNOSTICS, INC.
6. ILLUMINA, INC
7. INTEGRAGEN S.A
8. LABORATORY CORPORATION OF AMERICA HOLDINGS
9. LUMINEX CORPORATION
10. MOLECULARMD, CORP
11. NATERA, INC
12. OXFORD BIODYNAMICS LIMITED
13. PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
14. PERKINELMER, INC.
15. QIAGEN N.V.
16. ROCHE DIAGNOSTICS CORPORATION
